Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Navigating FDA Shakeups and Obesity Drug Wars

Behind the Headlines Episode 28

Ask the Expert

Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up

Drug Digest February 2026 

How It Helps Avoid Facility and Equipment Problems

A “Plan, Prevent, Prove” Approach

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

ESTEVE CDMO (actively operating under the Esteve Química brand) announced on July 31, 2025 that it has acquired Regis Technologies, an API contract development and manufacturing organization (CDMO) in Chicago. The acquisition expands ESTEVE’s API contract development and manufacturing services in the United States from pre-clinical to commercial manufacturing.

ESTEVE CDMO, headquartered in Barcelona, is a global pure-play CDMO that specializes in small-molecule APIs, intermediates, spray drying technologies, and high-potency API manufacturing. To these services, Regis Technologies brings process R&D; analytical and stability; current good manufacturing practice (GMP) API manufacturing; chemistry, manufacturing, and controls support; and chromatography products.

"We are proud to strengthen our CDMO solutions for pharmaceutical innovators through this acquisition, while welcoming around 70 skilled professionals to our US team," said Joan Petit, chief industrial operations officer of ESTEVE and general manager of Esteve CDMO (Esteve Química), in a press release (1).

"This acquisition enhances our early-stage development capabilities, and expands our global manufacturing footprint, allowing us to have an integrated service offering to better respond to our customers' needs," Andrea Oro, global head of Commercial Operations and Strategy, added.

"We are happy to join a company that shares our same values, a company that is also family-owned, with more than 90 years of experience, that is committed to people and focused on delivering long-term value to customers," said Scott Aladeen, president and CEO of Regis Technologies, in the release.

ESTEVE acquires symptomatic medullary thyroid cancer treatment

In June 2025, ESTEVE, the company’s pharmaceutical development division, acquired the rights to Caprelsa (vandetanib) in more than 50 countries from Sanofi. Caprelsa (vandetanib) is a treatment for adults and children five years of age and above with aggressive symptomatic medullary thyroid cancer.

"Medullary thyroid carcinoma is a rare neuroendocrine tumor that can produce calcitonin from parafollicular cells. The treatment of resectable disease is surgery (2). When the disease is not technically resectable, this treatment provides a long-lasting slowdown of disease progression. We at ESTEVE are proud to join the fighting effort of the patients diagnosed with this carcinoma and their healthcare professionals, with the ambition to continue improving patient's health and lives," José María Giménez-Arnau, chief scientific & medical officer of ESTEVE, said in a press release (3).

Other recent acquisitions by the company include the purchase of a business specializing in rare and ultra-rare endocrinology and onco-endocrinology diseases in April 2024 and a license for a biologic treatment for children and adolescents aged 2–18 years old with severe primary insulin-like growth factor 1 deficiency in April 2025.

"We are proud to announce that we are increasing our portfolio of highly specialized therapies. Caprelsa will help us improve the lives of patients all around the world. This is a step forward in ESTEVE's international journey focused on highly specialized treatments for high unmet medical needs of patients," Jacob Tolstrup, chief commercial officer of ESTEVE, said in the press release (3).

ESTEVE CDMO. ESTEVE CDMO Acquires Regis Technologies, Expanding US Presence and Capabilities. Press Release. July 31, 2025. 

https://www.esteve.com/global/media/news/esteve-acquires-regis-technologies-expanding-u-s-presence-and-capabilities

American Thyroid Association. Cancer of the Thyroid. Thyroid.org (accessed Aug.6, 2025). 

https://www.thyroid.org/medullary-thyroid-cancer/

ESTEVE. ESTEVE to Acquire Medicine to Treat Medullary Thyroid Cancer. Press Release. June 30, 2025. 

https://www.esteve.com/global/media/news/esteve-to-acquire-medicine-to-treat-medullary-thyroid-cancer

Articles

ESTEVE CDMO, operating under the Esteve Química brand, has acquired Regis Technologies, enhancing its API contract development and manufacturing services in the US. This acquisition strengthens ESTEVE's capabilities from pre-clinical to commercial manufacturing, adding process R&D, GMP API manufacturing, and more. Additionally, ESTEVE's pharmaceutical division acquired Caprelsa (vandetanib) for treating aggressive symptomatic medullary thyroid cancer, expanding its portfolio of specialized therapies. These strategic moves align with ESTEVE's focus on highly specialized treatments for unmet medical needs, reinforcing its global presence and commitment to patient care.

The acquisition expands the CDMO’s small-molecule API development and manufacturing services in the US.

ESTEVE CDMO Acquires Regis Technologies

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

gemstones using infrared spectroscopy | Image Credit: © poco_bw - stock.adobe.com

 series, FDA details how a newly developed nuclear magnetic resonance (NMR) spectroscopy method enabled researchers at the agency’s Center for Drug Evaluation and Research (CDER) to characterize—crucially, in a non-invasive way—microstructure properties in complex, oil-in-water nanoemulsion ophthalmic formulations (1).

The research centered around difluprednate, which has been approved as an orphan drug to treat post-operative ocular pain and inflammation (1). It is insoluble in water and, as such, was formulated as an oil-in-water nanoemulsion.

CDER researchers have been developing NMR spectroscopy to characterize such formulations since 2018, and, according to FDA, the researchers’ work culminated in correlated microstructure changes being observed for the first time in nanoemulsion formulations.

® also explores applications of spectroscopy, namely ultraviolet (UV) spectroscopy as a continuous, in-line method to monitor cleaning processes to confirm cleanliness of equipment surfaces through final rinse water analysis (2).

“Results showed that in-line monitoring capability of UV spectroscopy enables continuous monitoring of the entire cleaning cycle and applicability to quality by design, process analytical technology, process digitalization, and sustainability goals of a Pharma 4.0 manufacturing facility,” the authors wrote.

Below are further implications of CDER’s work for formulation scientists, analytical chemists, and manufacturers of complex drug products.

For formulation scientists, the ability to noninvasively monitor nanoemulsion dynamics could lead to more robust excipient selection, formulation optimization, and stability prediction. For manufacturers, intact NMR may offer a quality control tool that minimizes sample manipulation while enhancing sensitivity to early signs of instability.

The study also demonstrated that different NMR relaxation times and diffusion coefficients can serve as surrogate indicators for microstructural changes, suggesting possible future development of NMR-based specifications for complex generics and innovator products alike.

Relevance for complex generics, quality assessment

FDA's emphasis on intact NMR aligns with its broader goals to facilitate the development of complex generics, particularly those containing nano-sized active or excipient particles. By enabling more precise characterization of reference listed drugs and their generic counterparts, this approach may support bioequivalence determinations and post-approval change assessments.

Furthermore, FDA noted that the study aligns with quality by design principles, offering a means to better understand critical quality attributes of nanoemulsions without disrupting the formulation environment.

The adoption of intact NMR as a regulatory science tool represents a meaningful step in enhancing FDA’s analytical capabilities for complex dosage forms. As nanotechnology-based drug products continue to enter the market, advanced tools like these will likely become essential in supporting both premarket evaluations and ongoing quality assurance.

“Based on data obtained in this study, intact NMR methods for characterization of nanoemulsion can now be recommended to generic drug sponsors,” FDA said in the blog post (1). “These sensitive and accurate analytical methods may save resources for [the] pharmaceutical industry, accelerate generic drug development, and enhance the quality assessment of these drugs, ultimately resulting in lower costs to [the] American public.”

Modern Intact NMR Approach Reveals Synchronized Microstructural Changes in Nanoemulsion Drug Formulations.

, last updated Aug. 4, 2025 (accessed Aug. 5, 2025).
2. Schallom, J, et al. 

In-Line UV Spectrometry Monitoring in Cleaning Validation.

The FDA has developed a nuclear magnetic resonance (NMR) spectroscopy method to non-invasively characterize microstructure properties in oil-in-water nanoemulsion ophthalmic formulations. This advancement, particularly for difluprednate, an orphan drug for post-operative ocular pain, marks the first observation of correlated microstructure changes in such formulations. The method offers potential for robust excipient selection, formulation optimization, and stability prediction. It aligns with FDA's goals for complex generics development, supporting bioequivalence determinations and quality assessments, and is recommended for generic drug sponsors to enhance quality and reduce costs.

A new nuclear magnetic resonance method reveals real-time, coordinated changes in nanoemulsion drugs, improving noninvasive analysis and regulatory evaluation.

FDA Adopts Intact NMR to Advance Nanoemulsion Drug Quality Assessment

Feliza Mirasol is the science editor for 

Eli Lilly and Company (Lilly) announced on July 30, 2025 results from a long-term extension (LTE) of a Phase III study (TRAILBLAZER-ALZ 2), which showed that participants treated with donanemab-azbt (brand name Kisunla) demonstrated slowing of decline (1)—a benefit that continued to grow over a span of three years, compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (2). Under the brand name Kisunla, donanemab-azbt was 

 for treating Alzheimer’s disease (AD) (3).

Participants in the Phase III study who began treatment at a later time still saw benefit; however, study participants who started treatment earlier significantly reduced the risk of progression to the next stage of AD compared to those who received treatment later (2). Data from the study were presented at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto, Canada, which occurred on July 27–30.

"The TRAILBLAZER-ALZ 2 long-term extension reaffirms that Kisunla delivered sustained clinical benefit that continued to increase over three years and a consistent safety profile," said Mark Mintun, MD, group vice-president, Neuroscience Research & Development, Eli Lilly and Company, in a company press release (1). "Participants continued to show meaningful outcomes, reinforcing the long-term value of early intervention."

This Phase III LTE study (TRAILBLAZER-ALZ 2 LTE) was a double-blind extension of the original Phase III clinical trial (TRAILBLAZER-ALZ 2) designed to evaluate the efficacy and safety of donanemab-azbt in individuals with early symptomatic AD (2). Participants originally treated with donanemab-azbt were either continued on the same treatment or were switched to placebo, while those initially on placebo began treatment with donanemab-azbt in a blinded manner. To assess outcomes against a matched, untreated population, an external comparator group from ADNI was used.

The key preliminary results from the LTE study include:

The demonstration that the donanemab-azbt benefit continued to grow over the course of three years in study participants treated with the therapy compared to those in the matched ADNI group. The data show that donanemab-azbt reduced cognitive decline by -0.6 at 18 months and -1.2 at 36 months based on the Clinical Dementia Rating Sum of Boxes (CDR-SB). These data came from patients initially treated with the therapy in the core study compared to the ADNI group.

An earlier start of treatment with donanemab-azbt reduced the risk of disease progression to the next stage by 27% on the Clinical Dementia Rating-Global Score (CDR-G) compared to the group who had delayed initiation of treatment.

More than 75% of participants treated with donanemab-azbt achieved amyloid clearance within 76 weeks from the start of treatment.

Observed data gathered after up to 2.5 years in participants who had completed treatment showed that the reaccumulation of amyloid plaque remained slow at a rate of approximately 2.4 CL/year, which was consistent with prior observations and modeling.

No new safety signals were observed in the study over the three-year period, which supports the established safety profile for donanemab-azbt.

Side effects include amyloid-related imaging abnormalities (ARIA) with edema/effusion (ARIA-E) and with hemorrhage/with hemosiderin deposition. These are side effects within the class of amyloid targeting therapies that do not usually cause any symptoms; however, serious and life-threatening symptoms can occur. ARIA can be fatal, according to Lilly in the release.

Lilly’s Kisunla (donanemab-azbt) Showed Growing Benefit Over Three Years in Early Symptomatic Alzheimer’s Disease

. Press Release. July 30, 2025.
2. National Library of Medicine. 

A Study of Donanemab (LY3002813) in Participants with Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

, May 4, 2025 (accessed Aug. 5, 2025).
3. FDA. 

Eli Lilly's long-term extension of the Phase III TRAILBLAZER-ALZ 2 study demonstrated that donanemab-azbt (Kisunla) significantly slowed cognitive decline in Alzheimer's patients over three years. Early treatment initiation notably reduced disease progression risk compared to delayed treatment. The study, presented at the 2025 Alzheimer's Association International Conference, confirmed sustained clinical benefits and a consistent safety profile. More than 75% of participants achieved amyloid clearance within 76 weeks, with slow amyloid plaque reaccumulation. No new safety concerns were identified, although amyloid-related imaging abnormalities remain a potential risk.

Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the decline of patients exhibiting early symptomatic Alzheimer’s disease. 

Lilly’s Kisunla Demonstrates Growing Benefit in Treating Early Alzheimer’s Disease

Chemical molecular formula hormone serotonin. Silhouette of a man head. Connected lines with dots background. | Image Credit: © JEGAS RA - stock.adobe.com

 has received final approval from FDA for an abbreviated new drug application (ANDA) for sertraline hydrochloride capsules, in 150mg and 200mg doses, as selective serotonin reuptake inhibitors (SSRIs) for the treatment of major depressive disorder (MDD) in adults and obsessive-compulsive disorder (OCD) in both adults and pediatric patients aged six and older (1).

FDA’s approval is the first in the United States for a generic form of the reference sertraline hydrochloride drug marketed by Almatica Pharma (1). US sales of the reference product in the 12 months ending in June 2025 totaled $35.5 million, according to IQVIA.

Zenara’s version has also been granted competitive generic therapy designation, under the terms of which Zenara’s ANDA has 180 days of marketing exclusivity in the US, commencing with the product’s launch.

"Receiving the first generic approval for sertraline hydrochloride capsules highlights Zenara's strong R&D capabilities and operational excellence,” Srinivas Arutla, PhD, CEO of Zenara, said in a press release (1). “We remain committed to our mission of delivering to patients early access to high-quality, affordable pharmaceuticals."

Finding suitable treatments for MDD has been a goal for drug developers in recent years. In 2023, Evecxia Therapeutics and Quotient Sciences 

 of a Phase I clinical testing program for Evecxia’s EVX-101, an adjunctive treatment for MDD for patients who experienced an inadequate response to first-line antidepressants such as SSRIs (2).

Below are some broader impacts to the pharmaceutical industry based on the news from Zenara.

FDA’s cell and gene therapy (CGT) pathway aims to incentivize applicants to pursue competitive generics in markets with insufficient generic competition. Companies achieving first‑approval status can secure a six‑month exclusivity window in the US. For R&D teams, this underlines the value of strategic application timing and patent‑challenge readiness, especially for legacy molecules with high sales but limited generic entrants.

Scientific teams should note the therapeutic significance of sertraline as a widely prescribed SSRI. Generics in this space must replicate key pharmaceutical properties—dissolution profile, impurity thresholds, and bioequivalence performance—to qualify for FDA approval.

Zenara’s successful development and scale‑up suggest strong end‑to‑end capabilities in formulation and manufacturing. Vertical integration appears central to their competitive positioning, enabling efficient API sourcing, scale‑up validation, and good manufacturing practice compliance to support timely ANDA filing and commercial launch. For drug manufacturing organizations, this vertical integration moves beyond a simple reference drug copy strategy toward more strategic, agile platforms that prioritize rapid ANDA execution and commercial readiness to capture CGT incentives.

Strategic considerations for stakeholders

 Companies working in drug discovery should monitor FDA CGT designations and Orange Book listings to identify potential high‑value targets for generic development when exclusivities expire.

 Intellectual property teams must assess active patents and exclusivities early to establish first‑to‑file status and preserve eligibility for CGT exclusivity.

 Launch timing is critical. To avoid forfeiture of CGT exclusivity, first approved applicants must commercially market within 75 days of approval. Coordination between regulatory, manufacturing, and commercial functions is therefore imperative.

The approval won by Zenara illustrates how generic developers can harness regulatory incentives to bring affordable versions of widely used molecules to market. For drug discovery and development professionals, it exemplifies an emerging business model: targeting established, high‑volume drugs through accelerated pathways, leveraging robust formulation science and tight regulatory execution, rather than pursuing novel chemical entities exclusively.

Zenara Pharma Receives US FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity.

 Press Release. Aug. 1, 2025.
2. Quotient Sciences. 

Evecxia Therapeutics Reports Favorable Data from a Phase I SAD/MAD Trial.

Zenara Pharma, a subsidiary of Biophore, has received FDA approval for the first generic version of sertraline hydrochloride capsules, used to treat major depressive disorder and obsessive-compulsive disorder. This approval grants Zenara 180 days of marketing exclusivity in the US. The development underscores Zenara's R&D capabilities and highlights the strategic importance of FDA's competitive generic therapy pathway. The approval exemplifies a business model focusing on established drugs through accelerated pathways, emphasizing formulation science and regulatory execution over novel chemical entities.

The company’s FDA-approved first generic sertraline capsules secured a 180‑day exclusivity period, highlighting strategic generic development pathways.

Zenara Secures First Generic Sertraline Approval from FDA, Plus Six Months of Market Exclusivity

The Evolving Field of Radiopharmaceuticals

Radiopharmaceuticals have been traditionally used to treat superficial tumors, according to Mike Ritchie, CCO at 

. As they have evolved, they have been used to treat internal tumors, and now the technology is transforming to be directed specifically so that they only impact the tumor and not other cells in the body.

“There's so much [that goes] into pharmaceutical development into making something that can be manufactured at scale. It can sit on a shelf for a while. We can administer it to a patient, and it behaves in the way that we want,” says Ritchie. “We're just learning how to apply what we learn from anybody drug conjugatesinto radio drug conjugates, so the chemistry of how to link this radio ligand to an antibody, something that will continue to evolve, and there's a real opportunity there to improve that, to improve the therapeutic activity.From the biology perspective, again, we're in our infancy and understanding what are the tumor types, or the molecular cohorts within a tumor that are more sensitive to radio ligands. Like any chemotherapy or any therapy, certain tumors will respond. Others will not. They'll develop resistance. And so really understanding the right cohorts of patients to treat is something that we're still learning, and I think we'll continue to learn as the clinical development of these programs evolves.”

Click the video above to watch the interview.

Videos

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target tumors without impacting other cells in the body.

Futuristic health tech. A smartwatch projects a holographic health dashboard, providing real-time body analytics and vital signs monitoring anytime, anywhere. | Image Credit: © woravut - stock.adobe.com

FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program, launched in November 2020 as a pathway to qualify novel drug development tools (DDTs) not fitting within existing agency qualification parameters, is transitioning to a permanent DDT qualification program, according to an FDA Voices blog post published July 31, 2025 by ShaAvhrée Buckman-Garner, MD, PhD, director of the Office of Translational Services at FDA’s Center for Drug Evaluation and Research (CDER), and Mary Thanh Hai, MD, acting director of CDER’s Office of New Drugs (1,2).

FDA defines DDTs as “methods, materials, or measures” with the potential to facilitate drug development, counting among them tools that may: help to enable remote or decentralized trials (e.g., patient-performed digital photography in dermatology trials), advance understanding of drugs (using tissue chips to assess safety or efficacy, or developing novel, nonclinical pharmacology or toxicology assays), or leverage digital health technologies—such as artificial intelligence (AI)-based algorithms or wearables used for patient assessment (2).

DDTs evaluated to be “qualified” have a proven, specific use, and can be incorporated into any drug development program for a particular purpose (1). FDA maintains a 

 of DDT qualification projects under the umbrella of both CDER and the Center for Biologics Evaluation and Research.

ISTAND is being transitioned to a permanent program based on a total of eight accepted submissions over its nearly five-year pilot phase: three AI-based tools, two animal-free tools to assess preclinical safety, two novel methods involving tissues, and a novel statistical approach (1). Some examples of advanced tools the program has helped facilitate the integration of include organ-on-a-chip models, digital health technologies like fitness trackers, and complex 

As FDA continues to provide feedback on the submissions that have been accepted, the transition of ISTAND to a permanent program has numerous potential effects on drug developers and manufacturers.

For those involved in early-stage drug discovery, ISTAND’s permanency offers a clearer regulatory pathway for leveraging unconventional tools to generate and validate drug candidates. This includes, for example, the use of machine learning algorithms to identify promising compounds or targets, or the application of wearable devices to monitor real-world outcomes in preclinical and early clinical studies.

Drug development teams stand to benefit through more consistent engagement with FDA scientists, potentially reducing regulatory uncertainty associated with novel methodologies. This regulatory support may lead to greater investment in, and adoption of, innovative approaches to trial design, patient stratification, endpoint selection, and safety monitoring.

While ISTAND is not directly focused on manufacturing processes, its emphasis on novel data collection and analysis techniques could influence manufacturing by fostering tools that enhance process monitoring, quality assurance, and continuous manufacturing. For instance, digital sensors that monitor physiochemical parameters during production, or AI models that optimize process controls, could eventually be submitted through ISTAND for qualification, if their intended use supports a regulatory decision related to a new drug application.

A key feature of the ISTAND program is its transparency and collaborative engagement with stakeholders. The qualification process involves public posting of DDT submissions, feedback from FDA reviewers, and potential publication of qualified tools for broader industry use. This not only facilitates innovation within individual sponsors’ programs but also accelerates collective learning across the sector.

The formal establishment of ISTAND reflects FDA’s evolving approach to supporting scientific innovation in drug development. By offering a defined path for the qualification of nontraditional tools, the program is expected to expand the toolkit available to researchers and developers, thereby enabling more efficient and patient-centric drug development.

FDA Advances Drug Development Innovation by Establishing ISTAND as Permanent Qualification Program.

, July 31, 2025 (accessed Aug. 4, 2025).
2. FDA. 

Innovative Science and Technology Approaches for New Drugs (ISTAND) Program.

, last updated July 31, 2025 (accessed Aug. 4, 2025).

The FDA's ISTAND pilot program, initiated in 2020 to qualify novel drug development tools (DDTs), is transitioning to a permanent qualification program. DDTs, defined as methods, materials, or measures, facilitate drug development through tools like AI algorithms and digital health technologies. Over its pilot phase, ISTAND accepted eight submissions, including AI-based tools and novel statistical approaches. The program's permanency offers a clearer regulatory pathway for unconventional tools, enhancing drug discovery, development, and manufacturing. ISTAND emphasizes transparency and collaboration, fostering innovation and expanding the toolkit for researchers and developers.

The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

Roche announced on July 28, 2025 that it presented new data from its development portfolio for Alzheimer’s disease (AD) at the 2025 Alzheimer’s Association International Conference (AAIC), held in Toronto, Canada, on July 27–30. The company is conducting research on AD across both its pharmaceutical and diagnostics portfolios (1).

On the pharmaceutical portfolio front, the company’s presentations at the conference included the latest results from an ongoing Phase Ib/IIa Brainshuttle AD study, which continue to support the rapid and robust reduction of amyloid plaques, and the design of Phase III studies (TRONTIER 1 and 2) using trontinemab—an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody—for early symptomatic AD. These Phase III studies are planned to start later in 2025. In addition, Roche also plans to conduct an additional Phase III trial that will investigate the use of trontinemab in preclinical AD as part of its growing programs for the disease. This additional trial will focus on individuals at risk of cognitive decline. The goal will be to potentially delay or prevent the progression of AD to the symptomatic stages.

“Alzheimer’s disease represents one of the greatest challenges in healthcare today, and tackling it requires early detection and effective therapeutics,” said 

, chief medical officer and head of Global Product Development, Roche, in a company press release (1). “Trontinemab is designed to target a key driver of Alzheimer’s disease biology more effectively in the brain.Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer’s disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition.”

On the diagnostic portfolio front and using both oral and poster presentations at AAIC 2025, Roche highlighted the potential of its Elecsys pTau217 product as a reliable and accessible blood-based biomarker test, which can provide comparable results to positron emission tomography (PET) scans and cerebrospinal fluid diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of AD, across care settings. Elecsys pTau217 will be used in the planned additional Phase III studies (TRONTIER).

“Blood based testing for Alzheimer’s disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis,” said Matt Sause, CEO of Roche Diagnostics, in the press release. “Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families.”

Roche cites that up to 75% of people living with symptoms of AD globally have not been diagnosed. Meanwhile, those who have been diagnosed were said to have waited an average of 2.8 years to get the diagnosis (2). Even fewer have received any form of treatment, according to Roche in the release. The company stated in the release that “[d]iagnostics play a crucial role in addressing the global challenge of Alzheimer’s, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments” (1).

Roche Presents New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC.

 Press Release. July 27, 2025.
2. Johns Hopkins Bloomberg School of Public Health. Life Expectancy Following Diagnosis of Alzheimer’s Disease Depends on Age at Diagnosis. 

https://publichealth.jhu.edu/2002/alzheimer-age

Roche has unveiled new data on Alzheimer's disease (AD) research at the 2025 Alzheimer's Association International Conference. The company is advancing its pharmaceutical and diagnostic portfolios, focusing on trontinemab, a bispecific monoclonal antibody targeting amyloid-beta, with Phase III trials planned for early symptomatic and preclinical AD. Roche's Elecsys pTau217 test, a blood-based biomarker, shows promise as a reliable alternative to PET scans for diagnosing amyloid pathology. The company emphasizes the importance of early detection and effective therapeutics in addressing the global AD challenge.

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical portfolios at this year’s AAIC.

Roche Reveals New Data from Alzheimer’s Disease Research at AAIC 2025

White House | Image Credit: © Zack Frank - stock.adobe.com

United States President Donald Trump has contacted 17 pharmaceutical companies, providing them with the step-by-step process he says they must take to lower prescription drug prices in the US to the lowest price offered among other developed nations (1). This strategy, known as the most-favored-nation (MFN) price, was first detailed by the White House 

Conversations began after executive order

The companies receiving letters on July 31 were 

According to the White House, following the issuing of the May 12 executive order, the Trump administration began discussions with pharmaceutical manufacturers about ways to achieve MFN pricing in the US. The issuing of the letters is an indication that the administration feels that proposals from the industry have fallen short (1).

A fact sheet summarizing the content of the letters said that the federal government will “deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices” if these companies fail to act (1). The letters set 

The White House lists four main steps it is requesting the 17 companies to take:

MFN prices must be offered to every Medicaid patient.

Manufacturers must specify that they will not offer better prices for new drugs to other developed nations than those offered in the US.

Efforts should be made to eliminate middlemen and sell medicines directly to patients, provided at prices no higher than the best price available in developed nations.

Raising of international prices should be supported by trade policy, with increased revenues from abroad directly reinvested into lowering prices for Americans.

This apparently imminent shift in US drug pricing policy has wide-ranging potential impacts across the pharmaceutical industry. Here are a few to watch for as this story develops.

The action may introduce substantial uncertainty into historical pricing models previously used to justify high initial launch prices in the US market. Specifically, drug developers pursuing novel therapies with high R&D costs could face additional hurdles in projecting return on investment. Companies may begin to rethink early-stage decisions, including therapeutic areas of focus, prioritization of pipelines, and clinical trial design, especially when working on therapies expected to launch first in the US.

Moreover, the directive to directly reinvest international revenue gains—if global prices increase—into US price reductions could discourage investment in markets with tighter pricing controls, thereby reshaping global clinical trial strategies and potentially delaying drug availability abroad. These tradeoffs could incentivize firms to prioritize assets with clearer pathways to MFN-compliant pricing structures.

Manufacturing and market access challenges

Adapting to MFN pricing may necessitate pharmaceutical companies making fundamental changes to their global pricing and market access strategies. Numerous multinational companies engage in tiered pricing, meaning country-specific prices are negotiated based on local healthcare infrastructure and purchasing power. The proposed MFN policy could undermine this model by disincentivizing offering lower prices abroad unless US prices are also reduced accordingly.

Manufacturing decisions, specially around scale and site selection, may be affected as well, as companies adjust to anticipated changes in demand—particularly if pricing pressures cause shifts in product access or payer coverage. Manufacturers may need to invest in enhanced cost-control measures and supply chain optimization to preserve margins under more uniform, globally benchmarked pricing.

Eliminating middlemen, such as pharmacy benefit managers, and enabling direct-to-patient sales could disrupt traditional distribution models. For established firms, compliance may require restructuring commercial operations, including patient support programs, channel strategies, and pricing transparency initiatives. Companies may need to invest further in digital infrastructure or third-party partnerships.

For smaller or emerging companies, these demands could increase the financial and logistical barriers to market entry, intensifying the need for strategic alliances with larger firms that possess the operational capacity to meet evolving federal expectations.

The 60-day window issued by the administration presents a relatively short timeframe for manufacturers to respond meaningfully. Firms will likely need to evaluate their current and upcoming pricing agreements globally, analyze the revenue impact of MFN pricing, and consider potential litigation or policy engagement strategies. While the administration has not outlined explicit enforcement mechanisms, the language in the fact sheet suggests the possibility of regulatory or trade-related consequences should manufacturers not comply voluntarily.

Still, this stands to be a potentially transformative moment for pharmaceutical pricing policy in the US. Stakeholders in discovery, development, and manufacturing will need to closely monitor policy developments and prepare for scenarios that may affect global revenue planning, R&D prioritization, and commercial model evolution.

Fact Sheet: President Donald J. Trump Announces Actions to Get Americans the Best Prices in the World for Prescription Drugs.

Fact Sheet: President Donald J. Trump Announces Actions to Put American Patients First by Lowering Drug Prices and Stopping Foreign Free-Riding on American Pharmaceutical Innovation.

 WhiteHouse.gov, May 12, 2025.
3. Hollan, M. 

President Trump Issues Letters to 17 Major Pharma Companies Demanding Action on Most-Favored-Nation Order.

President Trump has directed 17 pharmaceutical companies to adopt the most-favored-nation (MFN) pricing strategy, ensuring US drug prices match the lowest among developed nations. The administration's letters, following a May 2025 executive order, demand action within 60 days, threatening regulatory measures if unmet. The MFN policy could disrupt traditional pricing models, affecting drug discovery, manufacturing, and market access strategies. Companies may face challenges in maintaining margins and adapting distribution models, with potential impacts on global clinical trial strategies and investment in markets with strict pricing controls.

If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.

Trump Sends Letters to 17 Leading Pharma Companies Outlining Most-Favored-Nation Drug Pricing Protocol

Bio/pharmaceutical manufacturers are increasingly strained by evolving trade policies and tariff regimes, explained Jason Waite, international trade lead at Alston & Bird, in our 

 show more than three-quarters of UK businesses have already lost profit due to tariffs, with 91% expressing concern over the impact of tariffs in the next 12 months and nearly one-third saying they are “extremely concerned.” Companies are being forced to reassess operations, supply chains, and pricing strategies. “Adding to the confusion, President Trump has also announced wider tariffs against specific countries,” wrote Mike Hollan in our sister publication 

For those operating in the bio/pharmaceutical sector, tariffs have disrupted not only finished product shipments but also the flow of active pharmaceutical ingredients and raw materials critical for production, explains Waite. Regulatory complexities and inconsistent enforcement further compound these challenges, complicating long-term planning for compliance, cost forecasting, and sourcing.

The heightened sensitivity to trade policy in the sector underscores a broader concern: that global pharmaceutical manufacturing now depends on more than regulatory approval and technical quality; it also hinges on geopolitical stability and predictability in trade relationships.

Help us get a better picture of how new tariffs and trade policy have impacted you and your organization. Check back in a couple weeks to see where you stand among your peers! All who complete the survey will be entered for a chance to win a $25 Amazon gift card. See full rules below.


1. NO PURCHASE NECESSARY. OPEN ONLY TO LEGAL RESIDENTS OF THE UNITED STATES OF AMERICA WHO ARE AT LEAST 18 YEARS OLD AT TIME OF ENTRY. Void where prohibited by law. This sweepstakes begins on August 4, 2025 at 12:01 a.m. ET and ends on August 14, 2025 at 11:59 p.m. ET (“Promotion Period”). Sponsor’s computer is the official time keeping device for this Sweepstakes. Enter the Sweepstakes during the Promotion Period by: (1) Following the link to the Impacts of Tariffs & Trade Policy survey; and (2) fully completing and submitting your responses. Online entries must be received no later than 11:59 p.m. ET on August 14, 2025. Alternatively, anyone may enter the Sweepstakes by printing the words “Tarriff Sweepstake,” along with his or her name, title, date of birth, street address, city, state, zip, and phone number on a 3.5" by 5" white index card. Mail the card to MultiMedia Pharma Sciences, LLC Attn: C. Cole, 2 Commerce Drive, Cranbury, New Jersey 08512. To be considered eligible, entries must be received no later than August 14, 2025 at 11:59 p.m. ET. No methods of entry other than the methods specifically described herein will be accepted. Sponsor is not responsible for lost, late, misdirected or incomplete entries or unsuccessful attempts to enter. Incomplete entries and/or entries not received by the deadlines will not be eligible. Limit (1) one entry per person, per mailing address, per outer-mailing envelope, and per email address.

2. Winner will be selected in a random drawing from among all eligible entries received on or about August 15, 2025. Drawing will be conducted by MultiMedia Pharma Sciences whose decisions are final. Drawing times are subject to change or cancellation with or without notice. Odds of winning will depend upon the total number of eligible entries received. For winner’s name, send a separate self-addressed, stamped envelope to 2 Commerce Drive, Cranbury, NJ 08512 by September 15, 2025.

3. The prize (“Prize”) consists of the following: (1) Amazon Gift Card with Approximate Retail Value (“ARV”) of $25.00. Amazon is a registered trademark of Amazon.com, Inc. All rights reserved. Amazon.com, Inc. is not a participant or sponsor of this promotion.

4. The limit is one winner for the Prize. Winner will be notified by phone, email, overnight delivery or first class mail, as Sponsor shall determine. If Winner does not respond to Prize Notification as directed within five (5) days of the attempted notification date or if a Prize or Prize notification is returned as unclaimed or undeliverable, such Winner will be disqualified, Prize will be forfeited and an alternate winner will be selected. Upon disqualification, the Prize will be forfeited and no compensation will be given.

Prize is not transferable. No cash or prize substitutions, except the sponsor reserves the right to substitute prizes of equal or greater value. Acceptance of Prize constitutes permission to use that winner's name, likeness, and photo, and hometown for promotional and publicity purposes in any media

now known or later developed, worldwide, at no additional compensation unless prohibited by law. All costs and expenses associated with Prize acceptance and use not specified herein as being provided such as reservation fees, taxes, insurance and other expenses incurred by accepting the Prize are the sole responsibility of the Winner. By participating and accepting a prize, winner releases and agrees to hold harmless, MultiMedia Pharma Sciences, LLC, its respective parent company, subsidiaries, affiliates, service agencies, sponsors and any independent contractors of any kind arising in whole or in part, directly or indirectly, from acceptance, possession, use, or misuse of the prize or the participation in this sweepstakes or any sweepstakes-related activity.

5. This sweepstakes is open only to legal residents of the United States of America who are at least 18 years old at the time of entry. Void wherever prohibited by law. All federal, state, and local laws and regulations apply. Persons in any of the following categories are not eligible to participate or win a prize: (a) persons who since January 1, 2023 were or are employees or agents of MultiMedia Pharma Sciences, LLC, its respective parent company, subsidiaries, affiliates, service agencies, sponsors and any independent contractors of any kind of the above organizations; (b) individuals engaged in the development, production, or distribution of materials or the implementation of the sweepstakes and (c) immediate family of, or persons living in the same household as any person in any of the preceding categories.

6. Information collected by Sponsor in connection with this Sweepstakes may be used by Sponsor and shared with third parties involved in administration of the Sweepstakes. Information collected from entrants is subject to Sponsor’s Privacy Policy available at https://www.mjhlifesciences.com/privacy-policy/ Sponsor is not responsible for any disclosure made by the other or any third party. By participating in the Sweepstakes and providing your information, Entrants hereby agree to Sponsor’s collection and usage of their personal information and acknowledge that they have read and accepted Sponsor’s Privacy Policies.

7. This promotion is in no way sponsored, endorsed or administered by, or associated with Facebook, Instagram, X.com, LinkedIn, or Amazon. You understand that you are providing your information to Sponsor and not to Facebook, Instagram, X.com, LinkedIn. Facebook and Instagram are registered trademarks of Meta, Inc. X.com is a registered trademark of X Corp. LinkedIn is a registered trademark of LinkedIn Corporation. Amazon is a registered trademark of Amazon.com, Inc.

8. Sponsor reserves the right, to disqualify any individual found, in its sole opinion, to be tampering with the operation of the Sweepstakes; to be acting in violation of these Official Rules; or to be acting in an unsportsmanlike manner or with the intent to disrupt the normal operation of the Sweepstakes. Any use of robotic, automatic, macro, programmed, third party or like methods to participate in the Sweepstakes will void any attempted participation affected by such methods and the disqualification of the individual utilizing the same. CAUTION AND WARNING: ANY ATTEMPT TO DELIBERATELY DAMAGE ANY WEB SITE OR UNDERMINE THE LEGITIMATE OPERATION OF THIS PROMOTION IS A VIOLATION OF CRIMINAL AND CIVIL LAWS. SHOULD SUCH AN ATTEMPT BE MADE, THE SPONSOR RESERVES THE RIGHT TO SEEK DAMAGES OR OTHER REMEDIES FROM ANY SUCH PERSON(S) RESPONSIBLE FOR THE ATTEMPT TO THE FULLEST EXTENT PERMITTED BY LAW. Sponsor reserves the right to cancel, suspend and/or modify the Promotion, or any part of it, if any fraud, technical failures or any other factor beyond Sponsor’s reasonable control impairs the integrity or proper functioning of the Sweepstakes, as determined by Sponsor in its sole discretion. In such event, Sponsor reserves the right to award the prizes at random from among the eligible entries received up to the time of the impairment. If due to a printing, production or other error, more prizes are claimed than are intended to be awarded, Prize will be awarded in a random drawing from among all verified and validated entries. In no event will more than one Prize be awarded. In the event of any conflict with any Sweepstakes details contained in these Official Rules and Sweepstakes details contained in other Sweepstakes-related materials, the details of the Sweepstakes as set forth in these Official Rules shall prevail. 9. By entering, each entrant agrees for entrant and for entrant’s heirs, executors, and administrators (a) to release and hold harmless MultiMedia Pharma Sciences, LLC, Amazon.com, Inc, Meta, Inc., X Corp., LinkedIn Corporation and their respective officers, directors, and employees (collectively, “Released

Parties”) from any liability, illness, injury, death, loss, litigation, or damage that may occur, directly or indirectly, whether caused by negligence or not, from such entrant’s participation in the Sweepstakes and/or his/her acceptance, possession, use, or misuse of any prize or any portion thereof; (b) that Released Parties have neither made nor are in any manner responsible or liable for any warranty, representation or guarantee, express or implied, in fact or in law, with respect to any prize, including, without limitation, to such prize’s quality or fitness for a particular purpose; and (c) to be bound by these Official Rules and to waive any right to claim any ambiguity or error therein or in the Sweepstakes itself, and to be bound by all decisions of the Sponsor, which are binding and final. Failure to comply with these conditions may result in disqualification from the Sweepstakes at Sponsor’s sole discretion. Sponsor reserves the right to cancel, suspend and/or modify the Sweepstakes, or any part of it, if any fraud, technical failures or any other factor beyond Sponsor’s reasonable control impairs the integrity or proper functioning of the Sweepstakes, as determined by Sponsor in its sole discretion. Sponsor makes no warranties, and hereby disclaims any and all warranties, express or implied, concerning any prize furnished in connection with the Sweepstakes. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, SUCH PRIZES ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND SPONSOR HEREBY DISCLAIMS ALL SUCH WARRANTIES, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND/OR NON-INFRINGEMENT.

10. This Promotion is subject to all applicable federal, state, and local laws and regulations. Issues concerning the construction, validity, interpretation and enforceability of these Official Rules shall be governed by the laws of the State of New Jersey, without regard to any principles of conflict of laws. All disputes arising out of or connected with this Promotion will be resolved individually, and without resort to class action, exclusively by a state or federal court located in Middlesex County, New Jersey. Should there be a conflict between the laws of the State of New Jersey and any other laws, the conflict will be resolved in favor of the laws of the State of New Jersey. To the extent permitted by applicable law, all judgments or awards shall be limited to actual out-of-pocket damages (excluding attorneys’ fees) associated with participation in this Promotion and shall not include any indirect, punitive, incidental and/or consequential damages.

11. The Sponsor and Administrator of this Sweepstakes is MultiMedia Pharma Sciences, LLC, 2 Commerce Drive, New Jersey 08512.

Bio/pharmaceutical manufacturers face significant challenges due to evolving trade policies and tariffs, impacting profits and operational strategies. A substantial portion of UK businesses report profit losses and express concerns about future tariff impacts. Tariffs disrupt the supply chain, affecting both finished products and raw materials, while regulatory complexities add to the difficulties. The industry's reliance on geopolitical stability and predictable trade relationships is increasingly evident. Companies must navigate these complexities to ensure compliance and cost-effectiveness, highlighting the critical role of trade policy in global pharmaceutical manufacturing.

Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.

Survey: Impacts of Tariffs and Trade Policy on the Bio/pharmaceutical Industry

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA announced on July 31, 2025, that it is requiring changes to the safety labeling of all opioid pain medications so that the risks associated with the long-term use of these types of drugs are emphasized and explained. This change comes after FDA reviewed data showing the serious risk of misuse, addiction, and overdose.

Data from two large FDA-required observational studies, postmarketing requirements (PMR) 3033-1 and 3033-2, provided new data on how long-term opioid use can lead to serious side effects. These data combined with public comments, medical research, and a lack of studies on the long-term effectiveness of opioids led the agency to require the safety labeling changes so that health care professionals and patients can make more informed treatment decisions.

Clearer risk information, including a summary of study results showing the estimated risks for addiction, misuse, and overdose during long-term use

Stronger warnings that higher doses come with greater risks that remain over time

The removal of language that may be misinterpreted to support using opioid pain drugs indefinitely

Guidance reinforcing that long-acting or extended-release opioids should only be considered when other treatments, including shorter-acting opioids, are inadequate

A reminder that opioids should not be stopped suddenly in patients who may be physically dependent, to avoid serious harm

Additional information on drugs that can reverse an opioid overdose

Enhanced warning about combining opioids with other drugs that slow down the nervous system

New information about a serious brain condition that may occur after an overdose (toxic leukoencephalopathy)

Updates about opioid-related impacts on the esophagus.

Relevant drug manufacturers have 30 days to submit their labeling updates to FDA for review.The agency is also requiring an additional prospective, randomized, controlled clinical trial to examine the benefits and risks of long-term opioid use.

“The death of almost one million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,” said FDA Commissioner Marty Makary, MD, MPH, in a press release (1). “This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and post-market monitoring so that nothing like this ever happens again.”

“I know firsthand how devastating addiction is—not just for individuals, but for entire families and communities,” said Health and Human Services Secretary Robert F. Kennedy, Jr., in the release. “Today’s FDA action is a long-overdue step toward restoring honesty, accountability, and transparency to a system that betrayed the American people.”

 that 7-hydroxymitragynine (7-OH) products be classified under the Controlled Substance Act (2). A concentrated byproduct of the kratom plant, according to FDA, binds to opioid receptors and, therefore, has the potential for abuse. While there are no 7-OH drugs approved by FDA, the agency has stated that approximately 1.7 million Americans aged 12 and older have used products to self-treat pain, coughing, diarrhea, anxiety, and depression that are prepared from the leaves of Mitragyna speciosa, a tropical tree native to Southeast Asia (3).

Biopharma developers exploring kratom-based therapeutics are being urged to be cautious. Enhanced 7-OH products may raise concern over abuse liability and may face future regulatory scheduling, which could impact clinical research and investigational drug approval. The Drug Enforcement Administration, which has final scheduling authority, is reviewing FDA’s recommendation on 7-OH.

FDA. FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks. Press Release. July 31, 2025. 

https://www.fda.gov/news-events/press-announcements/fda-requires-major-changes-opioid-pain-medication-labeling-emphasize-risks

The FDA has mandated changes to the safety labeling of opioid pain medications to highlight the risks of long-term use, including addiction, misuse, and overdose. This decision follows data from observational studies and public input. The new labeling will include clearer risk information, stronger warnings, and guidance on opioid use. Additionally, the FDA is requiring a clinical trial to further assess long-term opioid use. The agency also recommended classifying 7-hydroxymitragynine products under the Controlled Substance Act due to their potential for abuse, impacting kratom-based therapeutic development.

The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse and addiction.

Featured Content

Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Behind the Headlines Episode 28

Ask the Expert

Drug Digest February 2026

A “Plan, Prevent, Prove” Approach